Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.38 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GRK2 | P25098 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3923436 | 0.92 | S1PR5 (0.42) | KMT2AMAPK14S1PR5GRK2ALDH1A1 | |
| SCHEMBL3917605 | 0.89 | CYP11B1 (0.47) | MAPK14FEN1S1PR5GRK2ALDH1A1 | |
| SCHEMBL3915575 | 0.89 | GRK2 (0.45) | MAPK14FEN1S1PR5GRK2 | |
| SCHEMBL3917400 | 0.88 | MRGPRX4 (0.43) | MAPK14S1PR5GRK2PTGER1 | |
| SCHEMBL3105830 | 0.86 | CYP11B1 (0.44) | MAPK14S1PR5GRK2PTGER1 | |
| SCHEMBL3923475 | 0.85 | S1PR5 (0.47) | MAPK14S1PR5GRK2SMN1; SMN2PTGER1 | |
| SCHEMBL3922800 | 0.84 | MRGPRX4 (0.40) | MAPK14S1PR5GRK2PTGER1 | |
| SCHEMBL3912899 | 0.84 | SMN1; SMN2 (0.43) | MEN1KMT2AMAPK14S1PR5GRK2 | |
| SCHEMBL3916324 | 0.84 | SMN1; SMN2 (0.44) | TP53MAPK14S1PR5GRK2ALDH1A1 | |
| SCHEMBL3915748 | 0.83 | GRK2 (0.41) | MAPK14FEN1S1PR5GRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | TK1, ABL1, ROR1 | MEN1 853/4885KMT2A 3205/4885TP53 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.